Trial Profile
VRC101: A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of a Prime-Boost HIV-1 Vaccination Schedule of a 6-Plasmid Multiclade HIV-1 DNA Vaccine, VRC-HIVDNA016-00-VP, Followed by a Recombinant Multiclade Adenoviral Vector HIV Vaccine
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs VRC-HIVADV014-00-VP (Primary) ; VRC-HIVDNA016-00-VP (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions; Therapeutic Use
- 01 Sep 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
- 01 Sep 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
- 17 Dec 2005 New trial record.